Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report)
Crossref DOI link: https://doi.org/10.1007/s40261-017-0602-4
Published Online: 2017-12-27
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Takahashi, Tomohiko
Hayata, Satoru
Kobayashi, Akihiro
Onaka, Yuna
Ebihara, Takeshi
Hara, Terufumi
Funding for this research was provided by:
GSK Japan
License valid from 2017-12-27